CTMX
CytomX Therapeutics, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeCytomX secured a meaningful $37M expansion of its Regeneron partnership with up to $4B in total potential value, but Q2 2026 results were materially weaker than expected with revenue collapsing 93% YoY to $1.4M due to non-recurring 2025 collaboration revenues and a net loss of $20.7M. The stock trades at $3.46, well below analyst targets of $6–$16, reflecting significant execution risk despite the strengthened pipeline partnership and oncology expertise added to the board.
Red flags
- •Q2 revenue collapsed 93% YoY ($1.4M vs $18.7M); H1 2026 revenue down 83% vs H1 2025
- •Q2 net loss of $20.7M significantly worse than prior-year $0.2M loss; H1 2026 swung to $38.9M net loss vs $23.4M net income in H1 2025
- •Missed earnings expectations: reported adjusted loss of $0.09/share vs $0.08 consensus
- •Operating expenses rose to $55.1M from $48.2M despite lower revenue; cash burn accelerating
- •Moderna collaboration paused pending 'future alignment' — loss of revenue runway from key partner
- •Stock trading 77–82% below analyst price targets, indicating significant valuation/credibility gap
Fund 13D/13G Filings (2)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).